
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. stands to benefit significantly from the anticipated growth in its DefenCath franchise, particularly through its expansion into total parenteral nutrition (TPN), which is expected to enhance revenue opportunities beyond 2027. The company projects a notable increase in DefenCath pricing, expecting it to triple to quintuple by late 2026, with a sales forecast of $100 million to $140 million for 2027, driven by improved reimbursement rates in the hemodialysis setting. Additionally, the acquisition of Momenta has diversified CorMedix's revenue streams, contributing approximately $140 million in proforma revenue and achieving over $35 million in operating synergies within a short timeframe, indicating strong operational execution and potential for further growth.
Bears say
Cormedix Inc. has issued revenue guidance for DefenCath that is significantly below both internal estimates and market consensus expectations for 2026 and 2027, indicating potential challenges in meeting projected sales. The company anticipates DefenCath revenues of $150 million to $170 million, a considerable decline from approximately $260 million in 2025, which underscores concerns over its market competitiveness, especially against generics like Heparin. Additionally, anticipated high discontinuation rates due to toxicity and drug-drug interactions, coupled with a substantial projected revenue decline after July 2026, further reinforce a negative outlook on Cormedix's financial viability.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares